EQS-News

CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis

Issuer: CureVac / Key word(s): Patent CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis 31.01.2023 / 14:12 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis

 

• CureVac recognized as a Top 100 innovator in acknowledgment of the company’s innovative strength and extensive intellectual property portfolio
• The company holds one of broadest intellectual property portfolios in mRNA technology

TÜBINGEN, Germany/ BOSTON, USA – January 31, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced its inclusion in the second annual “Innovation Momentum: The Global Top 100” report by LexisNexis. The Top 100 recognizes companies advancing innovative solutions to address today’s challenges and laying the intellectual property foundations for further breakthroughs. The LexisNexis report identifies companies shaping the future of science and technology by analyzing shifts in patent portfolio strength over the last two years.

“Our extensive intellectual property portfolio in mRNA technology is built on more than 20 years of scientific excellence and remains one of the field’s broadest portfolios in existence today,” said Franz-Werner Haas, Chief Executive Officer of CureVac. “Over the last two years and supported by CureVac’s foundational innovations, mRNA technology has proven to be critical in addressing public health needs amid the COVID-19 pandemic. From the beginning, we have translated our strong track record of innovation into valuable intellectual property. We continue to invest in innovations in this rapidly developing field to further grow the value of our extensive portfolio. As the pioneer in mRNA technology, we are very proud to receive this recognition.”